BRIEF-Neurogene Inc - Participant In Neurogene's Phase 1/2 Trial For Rett Syndrome Dies

Reuters11-22

Nov 21 (Reuters) - Neurogene Inc NGNE.O:

NEUROGENE INC - PARTICIPANT IN NEUROGENE'S PHASE 1/2 TRIAL FOR RETT SYNDROME DIES
NEUROGENE INC - FDA ALLOWS NEUROGENE TO PROCEED WITH PHASE 1/2 TRIAL USING 1E15 VG DOSE

Source text: [t.ly/aIzVh]

Further company coverage: NGNE.O

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2485423690?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-22 05:15","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2485423690","market":"us","top_or_hot":-1,"title":"BRIEF-Neurogene Inc - Participant In Neurogene's Phase 1/2 Trial For Rett Syndrome Dies","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Neurogene Inc - Participant In Neurogene's Phase 1/2 Trial For Rett Syndrome Dies</title></head><body><p><span>Nov 21 (Reuters)</span><span> - </span>Neurogene Inc <span>NGNE.O</span>:</p><ul><li><p><a href=\"https://laohu8.com/S/NGNE\">NEUROGENE INC</a> - PARTICIPANT IN NEUROGENE'S PHASE 1/2 TRIAL FOR RETT SYNDROME DIES</p></li><li><p>NEUROGENE INC - FDA ALLOWS NEUROGENE TO PROCEED WITH PHASE 1/2 TRIAL USING 1E15 VG DOSE</p></li></ul><p>Source text: [t.ly/aIzVh]</p><p>Further company coverage: <span>NGNE.O</span></p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Neurogene Inc - Participant In Neurogene's Phase 1/2 Trial For Rett Syndrome Dies</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Neurogene Inc - Participant In Neurogene's Phase 1/2 Trial For Rett Syndrome Dies\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-22 05:15 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241121:nFWN3MS13T:1><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>BRIEF-Neurogene Inc - Participant In Neurogene's Phase 1/2 Trial For Rett Syndrome DiesNov 21 (Reuters) - Neurogene Inc NGNE.O:NEUROGENE INC - PARTICIPANT IN NEUROGENE'S PHASE 1/2 TRIAL FOR RETT ...</p>\n\n<a href=\"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241121:nFWN3MS13T:1\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241121:nFWN3MS13T:1","article_id":"2485423690","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2485423690","pubTimestamp":1732223714,"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Neurogene Inc - Participant In Neurogene's Phase 1/2 Trial For Rett Syndrome DiesNov 21  - Neurogene Inc NGNE.O:NEUROGENE INC - PARTICIPANT IN NEUROGENE'S PHASE 1/2 TRIAL FOR RETT SYNDROME DIESNEUROGENE INC - FDA ALLOWS NEUROGENE TO PROCEED WITH PHASE 1/2 TRIAL USING 1E15 VG DOSESource text: [t.ly/aIzVh]Further company coverage: NGNE.O","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","NGNE":"NEUROGENE INC"},"translate_title":"简介-Neurogene Inc-Neurogene雷特综合征1/2期试验参与者死亡","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NGNE":0.9},"content_text":"BRIEF-Neurogene Inc - Participant In Neurogene's Phase 1/2 Trial For Rett Syndrome DiesNov 21 (Reuters) - Neurogene Inc NGNE.O:NEUROGENE INC - PARTICIPANT IN NEUROGENE'S PHASE 1/2 TRIAL FOR RETT SYNDROME DIESNEUROGENE INC - FDA ALLOWS NEUROGENE TO PROCEED WITH PHASE 1/2 TRIAL USING 1E15 VG DOSESource text: [t.ly/aIzVh]Further company coverage: NGNE.O","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2485423690"}